Benjamin Lowentritt and Alicia Morgans discuss the ProVent trial, the use of sipuleucel-T in newly diagnosed prostate cancer patients on active surveillance.  They discuss inclusion criteria, trial design and primary outcome measures which include assessing the efficacy of sipuleucel-T in reducing reclassification to a higher Gleason grade in patients on active surveillance. 

Biographies:

Alicia Morgans, MD, MPH

Benjamin H. Lowentritt, MD, FACS, Director, Minimally Invasive Surgery and Robotics, Chesapeake Urology Associates, Director, Prostate Cancer Care Program, Chesapeake Urology Associates, and Past President, Baltimore City Medical Society

Related Content: 

A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer

Read: Phase 3 ProVent Clinical Trial Evaluating Sipuleucel-T in Men on Active Surveillance Completes Enrollment